Bacterial Vaginosis (BV) also is referred to as nonspecific vaginitis, is a vaginal condition that can produce vaginal discharge and results from an overgrowth of certain kinds of bacteria in the vagina. In the past, the condition was called Gardnerella vaginitis, after the bacteria that were thought to cause the condition. However, the newer name, bacterial vaginosis, reflects the fact that there are a number of species of bacteria that naturally live in the vaginal area and may grow to excess, rather than a true infection with foreign bacteria, such as occurs with many sexually-transmitted disease (STDs).
Many women with Bacterial Vaginosis have no signs or symptoms at all. When symptoms do occur, the most common include: an abnormal amount of vaginal discharge, thin and grayish white vaginal discharge and vaginal odor. Symptoms of Bacterial Vaginosis, if present, can occur any time in the menstrual cycle, including before, during, or after the menstrual period. Certain risk factors have been identified that increase the chances of developing Bacterial Vaginosis. These risk factors for BV include: antibiotic use, intrauterine devices for birth control, and cigarette smoking.
Get FREE sample copy at:
The Bacterial Vaginosis market report also covers emerging drugs, current treatment practices, Bacterial Vaginosis market share of the individual therapies, current and forecasted Bacterial Vaginosis Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Bacterial Vaginosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Bacterial Vaginosis Market Key Facts
As per the American Sexual Health Association 2019, BV is a common gynecologic infection, affecting nearly 29% of women in the US.
As per the study conducted by David A. Eschenbach et al. (2007), BV is one of the most common infections among sexually active women that is responsive to antibiotics. BV is present in at least 15% of the sexually active population; this makes BV 3–4 times more common than urinary tract infections.
The United States has the highest percentage of prevalent diagnosed and treated patients of BV among the 7MM.
Key Benefits of Bacterial Vaginosis Market Report
Bacterial Vaginosis market report provides an in-depth analysis of Bacterial Vaginosis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Bacterial Vaginosis market report will help in developing business strategies by understanding the Bacterial Vaginosis Market trends & developments, key players and future market competition that will shape and drive the Bacterial Vaginosis market in the upcoming years.
The Bacterial Vaginosis market report covers Bacterial Vaginosis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Bacterial Vaginosis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
High prevalence rate of the indication in the female population is expected to act as a driver for the BV drug market in the 7MM region. BV is the most common type of vaginal infection affecting women aged between 15-44 years of age. BV is also highly prevalent in pregnant women. It is expected that around 15% of the pregnant women in the US suffer from BV.
The Bacterial Vaginosis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Bacterial Vaginosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Bacterial Vaginosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Bacterial Vaginosis Epidemiology
The Bacterial Vaginosis epidemiology section covers insights about historical and current Bacterial Vaginosis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Bacterial Vaginosis Drugs Uptake and Key Market Players
The Bacterial Vaginosis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bacterial Vaginosis market or expected to get launched in the market during the study period. The analysis covers Bacterial Vaginosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key players Bacterial Vaginosis market includes:
And many others.
Lyophilized Lactobacillus crispatus IP174178
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Bacterial Vaginosis Competitive Intelligence Analysis
4. Bacterial Vaginosis Market Overview at a Glance
5. Bacterial Vaginosis Disease Background and Overview
6. Bacterial Vaginosis Patient Journey
7. Bacterial Vaginosis Epidemiology and Patient Population
8. Bacterial Vaginosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Bacterial Vaginosis Unmet Needs
10. Key Endpoints of Bacterial Vaginosis Treatment
11. Bacterial Vaginosis Marketed Products
12. Bacterial Vaginosis Emerging Therapies
13. Bacterial Vaginosis Seven Major Market Analysis
14. Attribute Analysis
15. Bacterial Vaginosis Market Outlook (7 major markets)
16. Bacterial Vaginosis Access and Reimbursement Overview
17. KOL Views on the Bacterial Vaginosis Market.
18. Bacterial Vaginosis Market Drivers
19. Bacterial Vaginosis Market Barriers
21. DelveInsight Capabilities
DelveInsight’s Bacterial Vaginosis Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Bacterial Vaginosis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Bacterial Vaginosis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Bacterial Vaginosis market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States